Unbundling the Policy: IFRS 17's Two Critical Tests for Investment Components

Imagine buying a combo meal. You get a burger, fries, and a drink, all for one price. But what if the drink came with a collectible, limited-edition cup? Suddenly, part of what you bought has a distinct value of its own. In the world of insurance, IFRS 17 asks us to do something similar: to look at our insurance contracts and decide if any 'investment components' are distinct enough to be unbundled and accounted for separately.

First, let's be clear. We only separate an investment component if it is distinct. If it's non-distinct, it remains an integral part of the insurance contract and is accounted for under IFRS 17. The core of the issue, then, is not about separating non-distinct components, but rather identifying which ones are distinct in the first place. IFRS 17 gives us a clear, two-part test to make this determination.

The Two-Part Test for a 'Distinct' Investment

An investment component—an amount an insurer must repay a policyholder even if no insured event occurs—is considered distinct only if both of the following criteria are met.

Criterion 1: The Investment Component is Not Highly Interrelated with the Insurance Component

This is the 'are they joined at the hip?' test. If the value of the insurance coverage is directly affected by the value of the investment, they are highly interrelated and cannot be separated. Think of a variable annuity where the death benefit is a multiple of the underlying investment account's value. The insurance (the death benefit) and the investment (the account value) are inextricably linked. You can't value one without the other. In this case, they are non-distinct and stay bundled together under IFRS 17.

Conversely, if you have a simple term life policy with a separate, optional savings pot where the pot's value grows independently of the death benefit, they are likely not highly interrelated. This passes the first test for separation.

Criterion 2: A Separate, Similar Contract is Sold in the Market

This is the 'could it stand on its own?' test. The standard asks whether a contract with equivalent terms to the investment component is, or could be, sold separately in the same market by entities (either the insurer or others). Essentially, if the investment component looks and behaves just like a standalone financial instrument (which would be accounted for under IFRS 9), it passes this test.

For example, if the savings pot from our previous example is identical to a mutual fund product the insurer (or a competitor) already sells, then it meets this criterion. The component is clearly marketable as a separate financial instrument.

Why This Distinction Is Crucial

Getting this right is more than an academic exercise. If an investment component is deemed distinct because it meets both criteria, it is unbundled from the insurance contract and accounted for under IFRS 9 (Financial Instruments). The remaining insurance portion is treated under IFRS 17.

If the component fails even one of these tests, it is considered non-distinct. The entire contract, including the investment feature, falls under the IFRS 17 measurement model. This fundamentally changes how you measure liabilities, recognize revenue, and present your financial position, making it a critical judgment call for every actuary and finance leader navigating the IFRS 17 landscape.